헬스케어 AI 거버넌스 플랫폼 시장 규모, 점유율, 동향 분석 보고서 : 용도별, 도입 형태별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

Healthcare AI Governance Platform Market Summary

The global healthcare AI governance platform market size was valued at USD 1.1 billion in 2025 and is projected to grow from USD 1.3 billion in 2026 to USD 3.9 billion by 2033, at a CAGR of 17.3% from 2026 to 2033. North America dominated the market, accounting for accounting for a revenue share of 52.7% in 2025. The global market is experiencing rapid growth, driven by the increasing adoption of AI across healthcare and the rising need for regulatory compliance, transparency, and risk management. Growing investments in responsible AI, model monitoring, and data governance are accelerating the adoption of AI governance platforms among healthcare providers, pharmaceutical companies, and payers.

Global Healthcare AI Governance Platforms Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global healthcare AI governance platforms market report based on application, deployment, end use, and region.

• Application Outlook (Revenue, USD Billion, 2021 - 2033)
• AI inventory and registry
• Model validation
• Bias and fairness monitoring
• Performance and drift monitoring
• Regulatory documentation
• AI agent governance
• Deployment Outlook (Revenue, USD Billion, 2021 - 2033)
• Cloud-based
• On-premises
• End Use Outlook (Revenue, USD Billion, 2021 - 2033)
• Healthcare providers
• Payers
• Life science companies
  • Pharmaceutical companies
  • Medical device companies
• Regional Outlook (Revenue, USD Billion, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• MEA
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
  • 1.2.1. Application Segment
  • 1.2.2. Deployment Segment
  • 1.2.3. End Use Segment
• 1.3. Information analysis
  • 1.3.1. Market formulation & data visualization
• 1.4. Data validation & publishing
• 1.5. Information Procurement
  • 1.5.1. Primary Research
• 1.6. Information or Data Analysis
• 1.7. Market Formulation & Validation
• 1.8. Market Model
• 1.9. Total Market: CAGR Calculation
• 1.10. Objectives
  • 1.10.1. Objective 1
  • 1.10.2. Objective 2

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Insights Landscape

Chapter 3. Healthcare AI Governance Platforms Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
  • 3.2.3. Market opportunity analysis
  • 3.2.4. Market challenges analysis
• 3.3. Healthcare AI Governance Platforms Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTLE Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
    • 3.3.2.4. Environmental Landscape
    • 3.3.2.5. Legal Landscape
    • 3.3.2.6. Social Landscape

Chapter 4. Healthcare AI Governance Platforms Market: Application Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Healthcare AI Governance Platforms Market Application Movement Analysis
• 4.3. Global Healthcare AI Governance Platforms Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Billion)
• 4.4. AI inventory and registry
  • 4.4.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
• 4.5. Model validation
  • 4.5.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
• 4.6. Bias and fairness monitoring
  • 4.6.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
• 4.7. Performance and drift monitoring
  • 4.7.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
• 4.8. Regulatory documentation
  • 4.8.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
• 4.9. AI agent governance
  • 4.9.1. Market estimates and forecasts 2021 to 2033 (USD Billion)

Chapter 5. Healthcare AI Governance Platforms Market: Deployment Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Healthcare AI Governance Platforms Market Deployment Movement Analysis
• 5.3. Global Healthcare AI Governance Platforms Market Size & Trend Analysis, by Deployment, 2021 to 2033 (USD Billion)
• 5.4. Cloud-based
  • 5.4.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
• 5.5. On-premises
  • 5.5.1. Market estimates and forecasts 2021 to 2033 (USD Billion)

Chapter 6. Healthcare AI Governance Platforms Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Healthcare AI Governance Platforms Market End Use Movement Analysis
• 6.3. Global Healthcare AI Governance Platforms Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Billion)
• 6.4. Healthcare providers
  • 6.4.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
• 6.5. Payers
  • 6.5.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
• 6.6. Life science companies
  • 6.6.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
  • 6.6.2. Pharmaceutical companies
    • 6.6.2.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
  • 6.6.3. Medical device companies
    • 6.6.3.1. Market estimates and forecasts 2021 to 2033 (USD Billion)

Chapter 7. : Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2025 & 2033
• 7.2. Regional Market Dashboard
• 7.3. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
• 7.4. North America
  • 7.4.1. U.S.
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework/ reimbursement structure
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Billion)
  • 7.4.2. Canada
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework/ reimbursement structure
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Billion)
  • 7.4.3. Mexico
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework/ reimbursement structure
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Billion)
• 7.5. Europe
  • 7.5.1. UK
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. UK market estimates and forecasts 2021 to 2033 (USD Billion)
  • 7.5.2. Germany
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Billion)
  • 7.5.3. France
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. France market estimates and forecasts 2021 to 2033 (USD Billion)
  • 7.5.4. Italy
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/ reimbursement structure
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Billion)
  • 7.5.5. Spain
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework/ reimbursement structure
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Billion)
  • 7.5.6. Norway
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework/ reimbursement structure
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Billion)
  • 7.5.7. Sweden
    • 7.5.7.1. Key country dynamics
    • 7.5.7.2. Regulatory framework/ reimbursement structure
    • 7.5.7.3. Competitive scenario
    • 7.5.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Billion)
  • 7.5.8. Denmark
    • 7.5.8.1. Key country dynamics
    • 7.5.8.2. Regulatory framework/ reimbursement structure
    • 7.5.8.3. Competitive scenario
    • 7.5.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Billion)
• 7.6. Asia Pacific
  • 7.6.1. Japan
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Billion)
  • 7.6.2. China
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. China market estimates and forecasts 2021 to 2033 (USD Billion)
  • 7.6.3. India
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Regulatory framework/ reimbursement structure
    • 7.6.3.3. Competitive scenario
    • 7.6.3.4. India market estimates and forecasts 2021 to 2033 (USD Billion)
  • 7.6.4. Australia
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Regulatory framework/ reimbursement structure
    • 7.6.4.3. Competitive scenario
    • 7.6.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Billion)
  • 7.6.5. South Korea
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Regulatory framework/ reimbursement structure
    • 7.6.5.3. Competitive scenario
    • 7.6.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Billion)
  • 7.6.6. Thailand
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Regulatory framework/ reimbursement structure
    • 7.6.6.3. Competitive scenario
    • 7.6.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Billion)
• 7.7. Latin America
  • 7.7.1. Brazil
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Billion)
  • 7.7.2. Argentina
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Billion)
• 7.8. MEA
  • 7.8.1. South Africa
    • 7.8.1.1. Key country dynamics
    • 7.8.1.2. Regulatory framework/ reimbursement structure
    • 7.8.1.3. Competitive scenario
    • 7.8.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Billion)
  • 7.8.2. Saudi Arabia
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Regulatory framework/ reimbursement structure
    • 7.8.2.3. Competitive scenario
    • 7.8.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Billion)
  • 7.8.3. UAE
    • 7.8.3.1. Key country dynamics
    • 7.8.3.2. Regulatory framework/ reimbursement structure
    • 7.8.3.3. Competitive scenario
    • 7.8.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Billion)
  • 7.8.4. Kuwait
    • 7.8.4.1. Key country dynamics
    • 7.8.4.2. Regulatory framework/ reimbursement structure
    • 7.8.4.3. Competitive scenario
    • 7.8.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Billion)

Chapter 8. Competitive Landscape

• 8.1. Company/Competition Categorization
• 8.2. Strategy Mapping
• 8.3. Company Market Position Analysis, 2025
• 8.4. Company Profiles/Listing
  • 8.4.1. Ferrum
    • 8.4.1.1. Company overview
    • 8.4.1.2. Financial performance
    • 8.4.1.3. Product benchmarking
    • 8.4.1.4. Strategic initiatives
  • 8.4.2. ModelOp
    • 8.4.2.1. Company overview
    • 8.4.2.2. Financial performance
    • 8.4.2.3. Product benchmarking
    • 8.4.2.4. Strategic initiatives
  • 8.4.3. Monitaur
    • 8.4.3.1. Company overview
    • 8.4.3.2. Financial performance
    • 8.4.3.3. Product benchmarking
    • 8.4.3.4. Strategic initiatives
  • 8.4.4. ValidMind
    • 8.4.4.1. Company overview
    • 8.4.4.2. Financial performance
    • 8.4.4.3. Product benchmarking
    • 8.4.4.4. Strategic initiatives
  • 8.4.5. Holistic AI
    • 8.4.5.1. Company overview
    • 8.4.5.2. Financial performance
    • 8.4.5.3. Product benchmarking
    • 8.4.5.4. Strategic initiatives
  • 8.4.6. Solytics partner
    • 8.4.6.1. Company overview
    • 8.4.6.2. Financial performance
    • 8.4.6.3. Product benchmarking
    • 8.4.6.4. Strategic initiatives
  • 8.4.7. Pacific AI
    • 8.4.7.1. Company overview
    • 8.4.7.2. Financial performance
    • 8.4.7.3. Product benchmarking
    • 8.4.7.4. Strategic initiatives
  • 8.4.8. Vitea AI
    • 8.4.8.1. Company overview
    • 8.4.8.2. Financial performance
    • 8.4.8.3. Product benchmarking
    • 8.4.8.4. Strategic initiatives
  • 8.4.9. Cognome, Inc
    • 8.4.9.1. Company overview
    • 8.4.9.2. Financial performance
    • 8.4.9.3. Product benchmarking
    • 8.4.9.4. Strategic initiatives
  • 8.4.10. Qualified health
    • 8.4.10.1. Company overview
    • 8.4.10.2. Financial performance
    • 8.4.10.3. Product benchmarking
    • 8.4.10.4. Strategic initiatives